BioPulse
@Biotechnerd1
Biotech💯.Day-trader. 16 years experience. Long/Short/Options. Always look for +\- perspectives in Biotech. Not Investment Advice.Catalyst Trades Focus 🚀🚀🚀.
You might like
$SLNO - newest board member Prior to joining the Soleno Board, Mr. Hahn served as Chief Financial Officer of Verona Pharma PLC, through the phase 3 program and launch of its first approved product, from March 2020 until its acquisition by Merck & Co., Inc. for approximately $10…
$ICCM in the .80s today - not a surprise.
$ICCM will management announce financing on Monday (on top of ATM)? I do think they urgently need to resolve cash(lack of) situation in near term. Post marketing trial will also cost $$$. Just IMO - you probably get to buy this in the .80s next week.
13 vote · Final results
I get the feeling that $DNLI is at that $ALNY moment where it has finally got a PDUFA data for its transport technology which could eventually lead to a big and broad pipeline. The only difference is the market has not figured it out yet. It took a long time for them to catch on…
Back in $SNDX position. PDUFA on 10/25 and I expect approval. Will we see another run-up in the next 2 weeks? Please note: The FDA's decision may come earlier.
The limits of FDA flexibility are tested as a controversial Biohaven $BHVN drug decision nears statnews.com/2025/10/09/bio…
$DNLI - would love to see it close > 200MA. Stock made a 50% + move the last time it held it broke with conviction(June 2024). Big catalyst ahead should do it…
$LQDA Q3 prediction: 1. 2000-2500 scripts. I'm not sure if they will provide numbers up to November or a week into. Anything over 1800 is extraordinary for Yutrepia's first official full Q on the market. 2. $30-35M in Yutrepia sales. I have attached $VRNA sales as guidance and…
Our take on the $LQDA launch so far and litigation tinyurl.com/3a63dpbm. We employed a third party firm to survey 30 randomized doctors and we found 372 patients on Yutrepia versus 1,629 on Tyvaso. This would suggest that $LQDA is close to 20% of the market. As $LQDA…
$PHAT - interesting potential growth name under the radar. Cantor with $29 price target is significant. Looks good this morning👀. This one can make big moves quickly. $XBI
$NVO is acquiring $AKRO $54 per share plus a $6 VCR
$XBI 2 years chart! Finally, the $XBI breaks out the $103.52 resistance line & moving higher to the next target $108.05
$NCNA 5.2 to 6 reload area for some sales!
Few important points on $NCNA which make it interesting as a near-term catalyst trade: 👉 Cash runway confirmed through 2029 👉 Nasdaq listing compliance confirmed in early September 👉 Market Cap <$15mln (split adjusted) 👉 52 week range: $2.78 - $446 (😂) 👉 23% of shares…
$NCNA 150%+ swing idea ✅
$NCNA fresh high again 140% since posted my DD analysis swing idea sub $3 BUY
Did several deep dives on $NCNA back when it was in the high 2's, low 3's. Excited to see it getting the action it deservers now trading ~$7 I've done lots of deep dives on this page. Sometimes they don't hit and thats just the nature of the market. But sometimes they really…
1/ A biotech trading below cash, chasing a $7B+ cancer market NuCana $NCNA is trying to repeat history. The same chemistry that created $200B+ in antiviral blockbusters (like Sovaldi and Remdesivir) is now being applied to cancer. Two drugs, NUC-7738 and NUC-3373, could unlock…
United States Trends
- 1. Happy Birthday Charlie 48.4K posts
- 2. Good Tuesday 30.8K posts
- 3. #tuesdayvibe 3,303 posts
- 4. Shilo 1,326 posts
- 5. #NationalDessertDay N/A
- 6. #PutThatInYourPipe N/A
- 7. Pentagon 74.3K posts
- 8. #TacoTuesday N/A
- 9. #Worlds2025 42.7K posts
- 10. Standard Time 2,961 posts
- 11. Victory Tuesday N/A
- 12. Dissidia 6,375 posts
- 13. Happy 32nd 8,597 posts
- 14. Happy Birthday in Heaven 1,400 posts
- 15. Martin Sheen 6,427 posts
- 16. Janet Mills 1,507 posts
- 17. No American 64K posts
- 18. JPMorgan 3,001 posts
- 19. Presidential Medal of Freedom 29.2K posts
- 20. Time Magazine 17.8K posts
Something went wrong.
Something went wrong.